David Socks

David A. Socks was the founder of Avera Pharmaceuticals, Inc. (2002), Verus Pharmaceuticals, Inc. (2002), Oculir, Inc. (2003), Passage Bio, Inc. (2017), Incline Therapeutics, Inc. (2010) where the title held was President & Chief Operating Officer from 2010 to 2013, Mallinckrodt Hospital Products, Inc. (2004) where the title held was SVP-Corporate Development & Strategy from 2004 to 2011, Outpost Medicine, Inc. (2016) where the title held was Director from 2017 to 2021, Cadence Pharmaceuticals, Inc. (2004) where the title held was Senior VP-Corporate Development & Strategy from 2004 to 2010, and Phathom Pharmaceuticals, Inc. (2018) where the title held was Independent Director from 2020 to 2025.
Mr. Socks is also the founder of Somaxon Pharmaceuticals, Inc.,MiraMedica, Inc.,Arcutis Biotherapeutics, Inc.,Kanisa Pharmaceuticals, Inc.,Nexcida Therapeutics, Inc.,Scout Bio, Inc.,Recida Therapeutics, Inc...
Mr. Socks is currently Chairman at Eleusis Holdings Ltd. since 2021 and Managing Partner at Mountainfield Venture Partners LLC.
Former positions include Director at Eleusis Ltd. from 2021 to 2022, Advisor at Windamere Venture Partners LLC, Vice President-Finance at CelTor Biosystems, Inc., Senior Manager at Kaiser Associates, Inc. from 1995 to 1998, Chief Business Officer at HilleVax, Inc. from 2023 to 2024, and Venture Partner at Frazier Management LLC from 2014 to 2021.
Education includes an MBA from Stanford University conferred in 2000 and an undergraduate degree from Georgetown University conferred in 1995.